NFE2L2 pathway polymorphisms and lung function decline in chronic obstructive pulmonary disease.

An oxidant-antioxidant imbalance in the lung contributes to the development of chronic obstructive pulmonary disease (COPD) that is caused by a complex interaction of genetic and environmental risk factors. Nuclear erythroid 2-related factor 2 (NFE2L2 or NRF2) is a critical molecule in the lung's defense mechanism against oxidants. We investigated whether polymorphisms in the NFE2L2 pathway affected the rate of decline of lung function in smokers from the Lung Health Study (LHS)(n = 547) and in a replication set, the Vlagtwedde-Vlaardingen cohort (n = 533). We selected polymorphisms in NFE2L2 in genes that positively or negatively regulate NFE2L2 transcriptional activity and in genes that are regulated by NFE2L2. Polymorphisms in 11 genes were significantly associated with rate of lung function decline in the LHS. One of these polymorphisms, rs11085735 in the KEAP1 gene, was previously shown to be associated with the level of lung function in the Vlagtwedde-Vlaardingen cohort but not with decline of lung function. Of the 23 associated polymorphisms in the LHS, only rs634534 in the FOSL1 gene showed a significant association in the Vlagtwedde-Vlaardingen cohort with rate of lung function decline, but the direction of the association was not consistent with that in the LHS. In summary, despite finding several nominally significant polymorphisms in the LHS, none of these associations were replicated in the Vlagtwedde-Vlaardingen cohort, indicating lack of effect of polymorphisms in the NFE2L2 pathway on the rate of decline of lung function.

[1]  F. Speizer,et al.  Assessment of genetic and nongenetic influences on pulmonary function. A twin study. , 2015, The American review of respiratory disease.

[2]  R M Gardner,et al.  Reference spirometric values using techniques and equipment that meet ATS recommendations. , 2015, The American review of respiratory disease.

[3]  Lorna M. Lopez,et al.  Genome-wide association and large scale follow-up identifies 16 new loci influencing lung function , 2011, Nature Genetics.

[4]  E. Noguchi,et al.  An interaction between Nrf2 polymorphisms and smoking status affects annual decline in FEV1: a longitudinal retrospective cohort study , 2011, BMC Medical Genetics.

[5]  David M. Evans,et al.  A Comprehensive Evaluation of Potential Lung Function Associated Genes in the SpiroMeta General Population Sample , 2011, PloS one.

[6]  C. Hersh.  Faculty Opinions recommendation of Genome-wide association study identifies five loci associated with lung function. , 2010 .

[7]  Christoph Lange,et al.  Variants in FAM13A are associated with chronic obstructive pulmonary disease , 2010, Nature Genetics.

[8]  D. Postma,et al.  Meta-analyses on suspected chronic obstructive pulmonary disease genes: a summary of 20 years' research. , 2009, American journal of respiratory and critical care medicine.

[9]  D. Postma,et al.  Level and course of FEV1 in relation to polymorphisms in NFE2L2 and KEAP1 in the general population , 2009, Respiratory research.

[10]  L. Z. Akhmadishina,et al.  Polymorphism of the genes for antioxidant defense enzymes and their association with the development of chronic obstructive pulmonary disease in the population of Bashkortostan , 2009, Russian Journal of Genetics.

[11]  K. Shianna,et al.  A Genome-Wide Association Study in Chronic Obstructive Pulmonary Disease (COPD): Identification of Two Major Susceptibility Loci , 2009, PLoS genetics.

[12]  Scott T. Weiss,et al.  A Genome-Wide Association Study of Pulmonary Function Measures in the Framingham Heart Study , 2009, PLoS genetics.

[13]  Kim W. Carter,et al.  SimHap GUI: An intuitive graphical user interface for genetic association analysis , 2008, BMC Bioinformatics.

[14]  Masayuki Yamamoto,et al.  The Antioxidant Defense System Keap1-Nrf2 Comprises a Multiple Sensing Mechanism for Responding to a Wide Range of Chemical Compounds , 2008, Molecular and Cellular Biology.

[15]  J. Hogg,et al.  Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. , 2008, American journal of respiratory and critical care medicine.

[16]  Cleo C. van Diemen,et al.  Lung function loss, smoking, vitamin C intake, and polymorphisms of the glutamate-cysteine ligase genes. , 2008, American journal of respiratory and critical care medicine.

[17]  D. Postma,et al.  Heme oxygenase 1 variations and lung function decline in smokers: proof of replication , 2008, Journal of Medical Genetics.

[18]  R. Tkacova,et al.  Glutathione S-transferase and microsomal epoxide hydrolase gene polymorphisms and risk of chronic obstructive pulmonary disease in Slovak population. , 2008, Croatian medical journal.

[19]  Frank Dudbridge,et al.  Likelihood-Based Association Analysis for Nuclear Families and Unrelated Subjects with Missing Genotype Data , 2008, Human Heredity.

[20]  S. Hong,et al.  The role of Bach2 in nucleic acid-triggered antiviral innate immune responses. , 2008, Biochemical and biophysical research communications.

[21]  Santiago Rodríguez,et al.  Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX' , 2007, BMC Bioinformatics.

[22]  N. Anthonisen,et al.  Polymorphisms of interleukin-10 and its receptor and lung function in COPD , 2007, European Respiratory Journal.

[23]  M. Imboden,et al.  Glutathione S-transferase genotypes modify lung function decline in the general population: SAPALDIA cohort study , 2007, Respiratory research.

[24]  Cleo C. van Diemen,et al.  A Disintegrin and Metalloprotease 33 polymorphisms and lung function decline in the general population , 2006, European Respiratory Review.

[25]  T. Mak,et al.  DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2 , 2006, Proceedings of the National Academy of Sciences.

[26]  A. Kikuchi,et al.  Heme oxygenase-1 gene promoter polymorphism and decline in lung function in Japanese men , 2006, Thorax.

[27]  P. Demoly,et al.  Association of lung function decline with the heme oxygenase-1 gene promoter microsatellite polymorphism in a general population sample. Results from the European Community Respiratory Health Survey (ECRHS), France , 2006, Journal of Medical Genetics.

[28]  A. Kong,et al.  Regulation of Nrf2 transactivation domain activity by p160 RAC3/SRC3 and other nuclear co-regulators. , 2006, Journal of biochemistry and molecular biology.

[29]  D. DeMeo,et al.  Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.

[30]  Masayuki Yamamoto,et al.  Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. , 2006, The Journal of clinical investigation.

[31]  P. Valentin-Weigand,et al.  Mycobacterium paratuberculosis, Mycobacterium smegmatis, and lipopolysaccharide induce different transcriptional and post‐transcriptional regulation of the IRG1 gene in murine macrophages , 2006, Journal of leukocyte biology.

[32]  Daniel C Liebler,et al.  Specific Patterns of Electrophile Adduction Trigger Keap1 Ubiquitination and Nrf2 Activation* , 2005, Journal of Biological Chemistry.

[33]  J. Li,et al.  Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix , 2005, Heredity.

[34]  John M Pezzuto,et al.  Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  N. Laird,et al.  Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. , 2005, American journal of respiratory cell and molecular biology.

[36]  M. Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[37]  S. Biswal,et al.  Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. , 2004, The Journal of clinical investigation.

[38]  P. Paré,et al.  Glutathione S-transferase variants and their interaction with smoking on lung function. , 2004, American journal of respiratory and critical care medicine.

[39]  Masayuki Yamamoto,et al.  Identification of polymorphisms in the promoter region of the human NRF2 gene. , 2004, Biochemical and biophysical research communications.

[40]  S.-L. Cheng,et al.  Genetic polymorphism of epoxide hydrolase and glutathione S-transferase in COPD , 2004, European Respiratory Journal.

[41]  Ralf Janknecht,et al.  Concerted Activation of ETS Protein ER81 by p160 Coactivators, the Acetyltransferase p300 and the Receptor Tyrosine Kinase HER2/Neu* , 2004, Journal of Biological Chemistry.

[42]  D. Nyholt.  A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. , 2004, American journal of human genetics.

[43]  J. D. Engel,et al.  Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation , 2003, Nature Genetics.

[44]  R. Cole,et al.  Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[45]  C. Yoo,et al.  Lack of Association Between Glutathione S-transferase P1 Polymorphism and COPD in Koreans , 2002, Lung.

[46]  P. Paré,et al.  Antioxidant gene polymorphisms and susceptibility to a rapid decline in lung function in smokers. , 2002, American journal of respiratory and critical care medicine.

[47]  E. Silverman,et al.  Chronic obstructive pulmonary disease • 1: Susceptibility factors for COPD the genotype–environment interaction , 2002, Thorax.

[48]  E. Broadfield,et al.  Prospective study of diet and decline in lung function in a general population. , 2002, American journal of respiratory and critical care medicine.

[49]  J. Qin,et al.  Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator Activity by IκB Kinase , 2002, Molecular and Cellular Biology.

[50]  N J Wareham,et al.  Siblings of patients with severe chronic obstructive pulmonary disease have a significant risk of airflow obstruction. , 2001, American journal of respiratory and critical care medicine.

[51]  R. Lanz,et al.  RAC‐3 is a NF‐κB coactivator , 2000 .

[52]  N. Kudo,et al.  Oxidative Stress Abolishes Leptomycin B-sensitive Nuclear Export of Transcription Repressor Bach2 That Counteracts Activation of Maf Recognition Element* , 2000, The Journal of Biological Chemistry.

[53]  P. Cassano,et al.  Antioxidant nutrients and pulmonary function: the Third National Health and Nutrition Examination Survey (NHANES III). , 2000, American journal of epidemiology.

[54]  W. MacNee,et al.  Oxidants/antioxidants and COPD. , 2000, Chest.

[55]  J. Yim,et al.  Genetic susceptibility to chronic obstructive pulmonary disease in Koreans: combined analysis of polymorphic genotypes for microsomal epoxide hydrolase and glutathione S-transferase M1 and T1 , 2000, Thorax.

[56]  Han-Jong Kim,et al.  Steroid receptor coactivator-1 and its family members differentially regulate transactivation by the tumor suppressor protein p53. , 1999, Molecular endocrinology.

[57]  L. Madisen,et al.  Identification of Bach2 as a B‐cell‐specific partner for small Maf proteins that negatively regulate the immunoglobulin heavy chain gene 3′ enhancer , 1998, The EMBO journal.

[58]  H. Schünemann,et al.  Oxidative stress and lung function. , 1997, American journal of epidemiology.

[59]  R. Evans,et al.  Nuclear Receptor Coactivator ACTR Is a Novel Histone Acetyltransferase and Forms a Multimeric Activation Complex with P/CAF and CBP/p300 , 1997, Cell.

[60]  W. Bailey,et al.  Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. , 1995, JAMA.

[61]  N. Copeland,et al.  Cloning and analysis of gene regulation of a novel LPS-inducible cDNA , 1995, Immunogenetics.

[62]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[63]  A. Buist,et al.  The Lung Health Study. Baseline characteristics of randomized participants. , 1993, Chest.

[64]  Ja.  Chronic Obstructive Pulmonary Disease , 1986 .

[65]  R. Peto,et al.  The natural history of chronic airflow obstruction. , 1977, British medical journal.

[66]  A. Hofman,et al.  Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function , 2010, Nature Genetics.

[67]  C. Carlson,et al.  Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. , 2004, American journal of human genetics.

[68]  J. Qin,et al.  Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by I kappa B kinase. , 2002, Molecular and cellular biology.

[69]  D. Postma,et al.  Chronic obstructive pulmonary disease. , 2002, Clinical evidence.

[70]  R. Lanz,et al.  RAC-3 is a NF-kappa B coactivator. , 2000, FEBS letters.

[71]  S. Shibahara,et al.  Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. , 2000, American journal of human genetics.

[72]  J. D. Engel,et al.  Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. , 1999, Genes & development.

[73]  A. Buist,et al.  Spirometry in the Lung Health Study. 1. Methods and quality control. , 1991, The American review of respiratory disease.

[74]  A. Buist,et al.  Spirometry in the Lung Health Study , 1991 .

[75]  Genome-wide Association Study Identifies BICD1 as a Susceptibility Gene for Emphysema , 2022 .